# Eton Pharmaceuticals

Type: Company (ETON)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/eton-pharmaceuticals
Canonical HTML page: https://getbiobrief.com/entity/eton-pharmaceuticals

## Timeline

- **2026-09-03**: Jefferson Capital dividend payable — Quarterly cash dividend of $0.24 per share is payable to shareholders.
- **2026-08-24**: Jefferson Capital dividend record date — Shareholders of record at close of business on August 24, 2026 qualify for the $0.24 per share dividend.
- **2026-08-13**: Q2 2026 earnings releases — Eton, Dawson, and Jefferson Capital report Q2 2026 financial results, with releases distributed at 20:30 UTC.
- **2026-06-30**: Q2 2026 reporting period ends — Eton Pharmaceuticals, Dawson Geophysical, and Jefferson Capital close the second quarter ended June 30, 2026.
- **2026-05**: HEMANGEOL relaunch — Eton relaunches HEMANGEOL in May 2026 with full Eton Cares patient support, including $0 copay for eligible patients.

## Recent coverage (1 stories)

### Eton Q2 Revenue Jumps 99% to $37.6M; FY Guide Raised to $145M
2026-08-13 22:06:32 · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Eton Pharmaceuticals grew Q2 2026 revenue 99% to $37.6 million on rare disease and pediatric endocrinology strength, relaunched HEMANGEOL, and licensed late-stage ASN-001. Bio investors should watch margin guidance and pipeline execution.
Full story: https://getbiobrief.com/story/eton-pharma-q2-2026-rare-disease-growth

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.